Butyrate-producing <i>Faecalibacterium prausnitzii</i> suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathwayOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study characterized the gut microbiota of patients with natural killer/T-cell lymphoma (NKTCL), an aggressive malignancy with a poor prognosis, using shotgun metagenomic sequencing. The researchers aimed to identify marker species linked to disease outcomes and to test whether specific gut bacteria could act as probiotics to slow NKTCL progression. They combined cross-sectional microbiota profiling with in vivo and in vitro tumor models, plus metabolomics, RNA sequencing, chromatin immunoprecipitation sequencing, Western blot, immunohistochemistry, and gene knockdown experiments to trace the underlying mechanism.
Who was studied?
The study drew on two Chinese cohorts of NKTCL patients, with findings validated in an independent Korean cohort. Cox proportional hazards models were used to relate microbial marker species to patient survival outcomes across these cohorts. Beyond the human cohorts, the mechanistic work relied on in vivo and in vitro tumor models rather than additional patient populations.
What were the most important findings?
NKTCL patients showed marked gut microbiota dysbiosis, most notably a reduction in Faecalibacterium prausnitzii, a butyrate-producing commensal. This depletion correlated strongly with shorter patient survival. The abstract further indicates that F. prausnitzii demonstrated antitumour properties against NKTCL, with the fuller mechanistic work pointing toward suppression of the JAK-STAT pathway as noted in the study title.
What are the greatest implications of this study?
The findings position F. prausnitzii, a butyrate-producing anti-inflammatory commensal, as a potential prognostic marker and probiotic candidate in NKTCL, a cancer with few therapeutic levers. Restoring this depleted organism could represent a novel adjunct strategy to dampen tumor-promoting JAK-STAT signaling. These results support further investigation into microbiome-targeted interventions for aggressive lymphomas where gut dysbiosis tracks with clinical outcomes.